{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:28:09Z","timestamp":1767864489947,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jcyt.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T17:46:29Z","timestamp":1557510389000},"page":"725-737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors"],"prefix":"10.1016","volume":"21","author":[{"given":"Laura F.","family":"Newell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsea M.","family":"Shoop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah J.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara N.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogelyn P.","family":"Kwock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol E.","family":"Jacoby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Slater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryon E.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casondra","family":"Ottowa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Cota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy L.","family":"Appel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2019.04.001_bib0001","unstructured":"D'Souza A, Zhu, X. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2016."},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.001_bib0002","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.bbmt.2014.05.003","article-title":"Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"20","author":"Duong","year":"2014","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.001_bib0003","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/sj.bmt.1702073","article-title":"Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors","volume":"24","author":"Martinez","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jcyt.2019.04.001_bib0004","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.1999.17.7.2160","article-title":"High-versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34(+) immunoselection","volume":"17","author":"Engelhardt","year":"1999","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.jcyt.2019.04.001_bib0005","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1200\/JCO.2001.19.16.3685","article-title":"Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis","volume":"19","author":"Cutler","year":"2001","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.001_bib0006","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2002-01-0011","article-title":"Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial","volume":"100","author":"Flowers","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.001_bib0007","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-011-1299-8","article-title":"Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials","volume":"91","author":"Chang","year":"2012","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.001_bib0008","article-title":"Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults","author":"Holtick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.001_bib0009","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2014.12.007","article-title":"Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis","volume":"94","author":"Holtick","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.001_bib0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"key":"10.1016\/j.jcyt.2019.04.001_bib0011","unstructured":"NEUPOGEN (Filgrastim) - FDA. In. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/103353s5184lbl.pdf."},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.001_bib0012","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2012.74","article-title":"Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization","volume":"47","author":"Chen","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jcyt.2019.04.001_bib0013","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1111\/trf.13143","article-title":"Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation","volume":"55","author":"Watz","year":"2015","journal-title":"Transfusion"},{"issue":"10","key":"10.1016\/j.jcyt.2019.04.001_bib0014","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1111\/trf.13262","article-title":"Defining the quality of hematopoietic stem cell products: the devil is in the details","volume":"55","author":"Tanhehco","year":"2015","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.jcyt.2019.04.001_bib0015","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3324\/haematol.2015.134841","article-title":"Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation","volume":"101","author":"Martin","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0016","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.bbmt.2015.01.025","article-title":"Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"21","author":"Remberger","year":"2015","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.001_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2141.2001.02468.x","article-title":"Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose","volume":"112","author":"Dominietto","year":"2001","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0018","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/jca.21278","article-title":"Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease","volume":"28","author":"Gomez-Almaguer","year":"2013","journal-title":"J Clin Apher"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0019","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.leu.2403718","article-title":"High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation","volume":"19","author":"Baron","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2019.04.001_bib0020","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3389\/fimmu.2016.00523","article-title":"Graft immune cell composition associates with clinical outcome of allogeneic hematopoietic stem cell transplantation in patients with AML","volume":"7","author":"Impola","year":"2016","journal-title":"Front Immunol"},{"issue":"21","key":"10.1016\/j.jcyt.2019.04.001_bib0021","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1200\/JCO.2014.60.1203","article-title":"High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning","volume":"33","author":"Reshef","year":"2015","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"24","key":"10.1016\/j.jcyt.2019.04.001_bib0022","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1182\/blood-2010-12-322214","article-title":"Twenty-five years of peripheral blood stem cell transplantation","volume":"117","author":"Korbling","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jcyt.2019.04.001_bib0023","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1200\/JCO.2013.54.4577","article-title":"Improved survival after transplantation of more donor plasmacytoid dendritic or naive T cells from unrelated-donor marrow grafts: results from BMTCTN 0201","volume":"32","author":"Waller","year":"2014","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0024","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.2005.05363.x","article-title":"Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning","volume":"128","author":"Panse","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.jcyt.2019.04.001_bib0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.exphem.2004.12.004","article-title":"CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies","volume":"33","author":"Cao","year":"2005","journal-title":"Exp Hematol"},{"issue":"6","key":"10.1016\/j.jcyt.2019.04.001_bib0026","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2004-04-1473","article-title":"Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose","volume":"105","author":"Cao","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2019.04.001_bib0027","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/bmt.2013.227","article-title":"A review of the haematopoietic stem cell donation experience: is there room for improvement?","volume":"49","author":"Billen","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.001_bib0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3324\/haematol.13668","article-title":"Severe events in donors after allogeneic hematopoietic stem cell donation","volume":"94","author":"Halter","year":"2009","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jcyt.2019.04.001_bib0029","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2013-12-542464","article-title":"Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation","volume":"123","author":"Pulsipher","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jcyt.2019.04.001_bib0030","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood-2008-08-175323","article-title":"Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program","volume":"113","author":"Pulsipher","year":"2009","journal-title":"Blood"},{"issue":"9 Suppl","key":"10.1016\/j.jcyt.2019.04.001_bib0031","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbmt.2008.05.018","article-title":"Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program","volume":"14","author":"Miller","year":"2008","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.jcyt.2019.04.001_bib0032","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/blood-2012-03-417667","article-title":"Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program","volume":"121","author":"Pulsipher","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.001_bib0033","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1703011","article-title":"Donating stimulated peripheral blood stem cells vs bone marrow: do donors experience the procedures differently?","volume":"27","author":"Switzer","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.001_bib0034","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bmt.1704245","article-title":"Differences between graft product and donor side effects following bone marrow or stem cell donation","volume":"32","author":"Favre","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jcyt.2019.04.001_bib0035","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2016.2520","article-title":"Comparison of patient-reported outcomes in 5-year survivors who received bone marrow vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial","volume":"2","author":"Lee","year":"2016","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0036","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.bmt.1701945","article-title":"Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation","volume":"24","author":"Bennett","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jcyt.2019.04.001_bib0037","first-page":"366","article-title":"The Cost of Hematopoietic Stem-Cell Transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0038","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbmt.2009.01.011","article-title":"Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications","volume":"15","author":"Majhail","year":"2009","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"5","key":"10.1016\/j.jcyt.2019.04.001_bib0039","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/bmt.2011.162","article-title":"Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation","volume":"47","author":"Svahn","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.001_bib0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ctr.12492","article-title":"Total costs and clinical outcome of hematopoietic stem cell transplantation in adults with leukemia: comparison between reduced-intensity and myeloablative conditioning","volume":"29","author":"Suh","year":"2015","journal-title":"Clin Transplant"},{"issue":"8","key":"10.1016\/j.jcyt.2019.04.001_bib0041","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/sctm.16-0487","article-title":"Concise review: the high cost of high tech medicine: planning ahead for market access","volume":"6","author":"Driscoll","year":"2017","journal-title":"Stem Cells Transl Med"},{"issue":"9","key":"10.1016\/j.jcyt.2019.04.001_bib0042","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.bbmt.2013.05.008","article-title":"Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature","volume":"19","author":"Shaughnessy","year":"2013","journal-title":"Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.jcyt.2019.04.001_bib0043","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532491930386X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S146532491930386X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:38:18Z","timestamp":1761442698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S146532491930386X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S146532491930386X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.04.001","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}